ZimVie (ZIMV) investor relations material

Executive summary

• Entered definitive agreement to be acquired for $19.00 per share in cash, expected to close by year-end 2025, pending regulatory and shareholder approvals.

• Will become a privately held company and delist from NASDAQ upon transaction completion.

• Completed sale of spine segment on April 1, 2024, for $377M, shifting focus to dental business.

• Net loss from continuing operations narrowed to $3.8M for Q2 2025 from $9.6M in Q2 2024.

• Comprehensive income for Q2 2025 was $13.2M, driven by favorable foreign currency translation.

Financial highlights

• Q2 2025 net sales were $116.7M, nearly flat year-over-year; six-month sales declined 2.7% to $228.7M.

• Operating profit for Q2 2025 was $1.3M, compared to a $6.7M loss in Q2 2024.

• Adjusted EBITDA from continuing operations was $17.5M, with a margin of 15.0%, up 150 basis points year-over-year.

• GAAP diluted EPS from continuing operations was $(0.14); adjusted diluted EPS was $0.26.

• Cash and cash equivalents were $70.2M as of June 30, 2025.

Outlook and guidance

• Fiscal 2025 guidance withdrawn due to pending acquisition; no conference call for the quarter.

• Management expects to complete restructuring activities by end of 2025.

• Available cash, operations, and credit facility expected to meet liquidity needs for at least 12 months.

• Ongoing evaluation of tariff impacts and optimization of global supply chain.